Aug 6 (Reuters) – Regeneron Pharmaceuticals Inc’s Eylea helped improve the vision of patients with diabetic macular edema (DME) significantly better than laser surgery in a pair of late… ...

A high-stakes legal fight between Regeneron and Amgen over the blockbuster eye drug Eylea is putting the U.S. patent system ...

Eylea is a prescription drug used to treat certain eye conditions. Learn about the drug’s dosages, forms, strengths, and more.

Doctors say they’re seeing an unexplained increase in a rare, frightening side effect in patients getting Regeneron Pharmaceuticals Inc.’s top-selling product, the blockbuster eye drug Eylea.

(Reuters) – Regeneron Pharmaceuticals Inc said U.S. health regulators approved the company’s eye drug Eylea for a new use, potentially boosting the already soaring sales of the drug tha… ...

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary endpoint and the only time stamp out of 10 in which the candidate ...

Like Eylea, Innovent’s anti-VEGF contender also needs to be injected into the eye. The recommended dosing for Eylea is every four weeks for the first 12 weeks, and then every eight weeks.

Eylea HD is supplied as either: A single-dose glass vial containing one Eylea HD 8 mg (0.07 mL of a 114.3 mg/mL solution); or. A vial kit with the following components: one Eylea HD 8 mg (0.07 mL ...

Eylea HD results were consistent across patients with branch RVOs and those with central retinal or hemiretinal vein occlusions. In the past three months, shares of REGN have plunged 35.7% ...

Additionally, about 90% of Eylea HD patients were able to maintain eight-week dosing intervals through the 36-week treatment period. In the QUASAR study, Eylea HD demonstrated a safety profile ...